Compare Recursion Pharmaceuticals Inc (RXRX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B), while Schlumberger NV trades at $48.94 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 34× Recursion Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Schlumberger NV for 99 Days on average.
| RXRX | SLB | |
|---|---|---|
Market Cap | $2.14B | $72.69B |
Volume | 30,789,535 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $6.79 | $60.10 |
52-Week Low | $2.84 | $31.72 |
Typical Hold Time | 22 Days | 99 Days |
Enterprise Value | $1.66B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
SLB trades at $47.96, down 4.08% on the day, amid a bearish technical signal. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Recent contract wins in the Rovuma Basin, Saudi Arabia, and Oman bolster revenue visibility. Cash flow from operations remains strong at $6.49B for 2025, though net cash flow was negative due to financing activities.
Analyst consensus is bullish with an 84.85% buy rating and a $64.58 price target, implying significant upside. Risks include exposure to oil price volatility and recent profit margin compression. The stock's current valuation metrics, including a P/E of 23.89, appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
